Abstract
This paper describes the synthesis, characterization, cytotoxicity of a new trinuclear Pt-Pd-Pt complex code named TH8 containing two 4-hydroxypyridine ligands bound to the central metal ion. In addition to its activity against human ovarian cancer cell lines: A2780, A2780cisR and A2780ZD0473R, cell uptake, level of DNA-binding and nature of interaction of the compound with pBR322 plasmid DNA have also been determined. TH8 is found to be less active than cisplatin against the parent cell line A2780 but is more active against the cisplatin-resistant cell line A2780cisR. Whereas the resistance factors for cisplatin as applied to the cell lines A2780 and A2780cisR, and A2780 and A2780ZD0473R are 12.9 and 3.0 respectively, the corresponding values for TH8 are 1.4 and 2.1. The results suggest that TH8 has been better able to overcome the resistance operating in A2780cisR cell line. Whereas cisplatin binds with DNA forming mainly intrastrand GG adduct that causes local bending of a DNA strand, TH8 is expected to bind with DNA forming mainly interstrand GG adducts that would cause more of a global change in DNA conformation.
Keywords: Cisplatin, BBR3464, 4-hydroxypyridine, Ovarian cancer, MTT
Medicinal Chemistry
Title: Synthesis, Activity and Binding with DNA of [{trans-PtCl(NH ) }2μ-{trans- Pd(4-hydroxypyridine) (H N(CH ) NH ) ]Cl (TH8)
Volume: 5 Issue: 4
Author(s): Fazlul Huq, Hasan Tayyem, Jun Qing Yu, Philip Beale and Keith Fisher
Affiliation:
Keywords: Cisplatin, BBR3464, 4-hydroxypyridine, Ovarian cancer, MTT
Abstract: This paper describes the synthesis, characterization, cytotoxicity of a new trinuclear Pt-Pd-Pt complex code named TH8 containing two 4-hydroxypyridine ligands bound to the central metal ion. In addition to its activity against human ovarian cancer cell lines: A2780, A2780cisR and A2780ZD0473R, cell uptake, level of DNA-binding and nature of interaction of the compound with pBR322 plasmid DNA have also been determined. TH8 is found to be less active than cisplatin against the parent cell line A2780 but is more active against the cisplatin-resistant cell line A2780cisR. Whereas the resistance factors for cisplatin as applied to the cell lines A2780 and A2780cisR, and A2780 and A2780ZD0473R are 12.9 and 3.0 respectively, the corresponding values for TH8 are 1.4 and 2.1. The results suggest that TH8 has been better able to overcome the resistance operating in A2780cisR cell line. Whereas cisplatin binds with DNA forming mainly intrastrand GG adduct that causes local bending of a DNA strand, TH8 is expected to bind with DNA forming mainly interstrand GG adducts that would cause more of a global change in DNA conformation.
Export Options
About this article
Cite this article as:
Huq Fazlul, Tayyem Hasan, Yu Qing Jun, Beale Philip and Fisher Keith, Synthesis, Activity and Binding with DNA of [{trans-PtCl(NH ) }2μ-{trans- Pd(4-hydroxypyridine) (H N(CH ) NH ) ]Cl (TH8), Medicinal Chemistry 2009; 5 (4) . https://dx.doi.org/10.2174/157340609788681449
DOI https://dx.doi.org/10.2174/157340609788681449 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Functional Nanogels for Biomedical Applications
Current Medicinal Chemistry Use of Toll-Like Receptor 3 Agonists Against Respiratory Viral Infections
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Transmembrane Phosphatases and Cancer Development, the Role of Protein Tyrosine Phosphatase-kappa (PTPκ) and Protein Tyrosine Phosphatase-mu (PTPμ)
Current Signal Transduction Therapy Myeloma Cells and Their Interactions With the Bone Marrow Endothelial Cells
Current Immunology Reviews (Discontinued) SAR, QSAR and Docking of Anticancer Flavonoids and Variants: A Review
Current Topics in Medicinal Chemistry Role of Resveratrol in Modulating microRNAs in Human Diseases: From Cancer to Inflammatory Disorder
Current Medicinal Chemistry Application of Pharmacogenomic Approaches in the Study of Drug Response in Complex Diseases
Current Pharmacogenomics Novel Ideas of Gene Therapy for Atherosclerosis: Modulation of Cellular Signal Transduction of TGF-β Family
Current Pharmaceutical Design Mitogen-activated Protein Kinase (MAPK) Interacting Kinases 1 and 2 (MNK1 and MNK2) as Targets for Cancer Therapy: Recent Progress in the Development of MNK Inhibitors
Current Medicinal Chemistry Adenovirus Vectors for Gene Therapy, Vaccination and Cancer Gene Therapy
Current Gene Therapy Disulfiram's Anticancer Activity: Evidence and Mechanisms
Anti-Cancer Agents in Medicinal Chemistry Pharmacological Interference With Protein-protein Interactions of Akinase Anchoring Proteins as a Strategy for the Treatment of Disease
Current Drug Targets The IGF-I/IGF-I Receptor Pathway: Implications in the Pathophysiology of Thyroid Cancer
Current Medicinal Chemistry Fibroblast Growth Factors in Development and Cancer: Insights from the Mammary and Prostate Glands
Current Drug Targets Patent Selections:
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Ovarian Cancer Biomarkers: A Focus on Genomic and Proteomic Findings
Current Genomics PARP Inhibitors: An Interesting Pathway also for Non-Small Cell Lung Cancer?
Current Pharmaceutical Design Proteomic Profiling of a Biomimetic Drug Delivery Platform
Current Drug Targets Impact of Oncogenic Protein Tyrosine Phosphatases in Cancer
Anti-Cancer Agents in Medicinal Chemistry Role of Focal Adhesion Kinase in Human Cancer: A Potential Target for Drug Discovery
Anti-Cancer Agents in Medicinal Chemistry